Negative regulation of CHK2 activity by protein phosphatase 2A is modulated by DNA damage

Cell Cycle

Volumn 9, Issue 4, 2010, Pages 736-747

  Freeman, Alyson K ^a,b   Dapic, Virna ^a   Monteiro, Alvaro N A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

CHK2; DNA damage; Phosphorylation; PP2A; Signaling

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; DOXORUBICIN; HYDROXYUREA; MITOMYCIN; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; SERINE; THREONINE; WORTMANNIN; ANTINEOPLASTIC ANTIBIOTIC; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ALPHA CHAIN; ARTICLE; CORRELATION ANALYSIS; DISSOCIATION; DNA DAMAGE; DNA STRAND; ENZYME ACTIVITY; ENZYME BINDING; ENZYME REGULATION; GAMMA IRRADIATION; HUMAN; HUMAN TISSUE; INFRARED RADIATION; IONIZING RADIATION; MOLECULAR RECOGNITION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RADIATION DOSE; CELL LINE; GAMMA RADIATION; KINETICS; METABOLISM; PHOSPHORYLATION;

ANTIBIOTICS, ANTINEOPLASTIC; CELL CYCLE PROTEINS; CELL LINE; DNA DAMAGE; DNA-BINDING PROTEINS; DOXORUBICIN; GAMMA RAYS; HUMANS; KINETICS; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 77953150977     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.4.10613     Document Type: Article

References (51)

1. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433-9.
2. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3:421-9. (Pubitemid 38340288)
3. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 2000; 97:10389-94.
4. Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 2000; 60:5934-6.
5. Melchionna R, Chen XB, Blasina A, McGowan CH. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol 2000; 2:762-5.
6. Xu X, Tsvetkov LM, Stern DF. Chk2 activation and phosphorylation- dependent oligomerization. Mol Cell Biol 2002; 22:4419-32.
7. Lee CH, Chung JH. The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation. J Biol Chem 2001; 276:30537-41.
8. Wu X, Chen J. Autophosphorylation of checkpoint kinase 2 at serine 516 is required for radiation-induced apoptosis. J Biol Chem 2003; 278:36163-8.
9. Ahn JY, Li X, Davis HL, Canman CE. Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J Biol Chem 2002; 277:19389-95. (Pubitemid 34967446)
10. Bartek J, Falck J, Lukas J. CHK2 kinase - a busy messenger. Nat Rev Mol Cell Biol 2001; 2:877-86.
11. Mochan TA, Venere M, DiTullio RA Jr, Halazonetis TD. 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res 2003; 63:8586-91.
12. Kurz EU, Douglas P, Lees-Miller SP. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 2004; 279:53272-81. (Pubitemid 40051831)
13. Buscemi G, Carlessi L, Zannini L, Lisanti S, Fontanella E, Canevari S, et al. DNA damage-induced cell cycle regulation and function of novel Chk2 phosphoresidues. Mol Cell Biol 2006; 26:7832-45.
14. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286:2528-31.
15. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002; 71:432-8. (Pubitemid 34800260)
16. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31:55-9.
17. de Bock GH, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet 2004; 41:731-5.
18. Wu X, Webster SR, Chen J. Characterization of tumor-associated Chk2 mutations. J Biol Chem 2001; 276:2971-4.
19. Falck J, Lukas C, Protopopova M, Lukas J, Selivanova G, Bartek J. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 2001; 20:5503-10. (Pubitemid 32889487)
20. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001; 353:417-39.
21. Virshup DM, Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol Cell 2009; 33:537-45.
22. Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 2009; 1795:1-15.
23. Xu Y, Xing Y, Chen Y, Chao Y, Lin Z, Fan E, et al. Structure of the protein phosphatase 2A holoenzyme. Cell 2006; 127:1239-51.
24. Cho US, Xu W. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 2007; 445:53-7. (Pubitemid 46067298)
25. Pallas DC, Cherington V, Morgan W, DeAnda J, Kaplan D, Schaffhausen B, et al. Cellular proteins that associate with the middle and small T antigens of polyomavirus. J Virol 1988; 62:3934-40.
26. Yang SI, Lickteig RL, Estes R, Rundell K, Walter G, Mumby MC. Control of protein phosphatase 2A by simian virus 40 small-t antigen. Mol Cell Biol 1991; 11:1988-95.
27. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 2002; 22:2111-23. (Pubitemid 34224619)
28. Suganuma M, Fujiki H, Suguri H, Yoshizawa S, Hirota M, Nakayasu M, et al. Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc Natl Acad Sci USA 1988; 85:1768-71. (Pubitemid 24315763)
29. Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, Minna J, et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998; 282:284-7. (Pubitemid 28487198)
30. Ruediger R, Pham HT, Walter G. Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. Oncogene 2001; 20:10-5. (Pubitemid 32142333)
31. Esplin ED, Ramos P, Martinez B, Tomlinson GE, Mumby MC, Evans GA. The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function. Genes Chromosomes Cancer 2006; 45:182-90.
32. McCright B, Rivers AM, Audlin S, Virshup DM. The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm. J Biol Chem 1996; 271:22081-9.
33. Zannini L, Lecis D, Lisanti S, Benetti R, Buscemi G, Schneider C, et al. Karyopherin-alpha2 protein interacts with Chk2 and contributes to its nuclear import. J Biol Chem 2003; 278:42346-51.
34. Boddy MN, Lopez-Girona A, Shanahan P, Interthal H, Heyer WD, Russell P. Damage tolerance protein Mus81 associates with the FHA1 domain of checkpoint kinase Cds1. Mol Cell Biol 2000; 20:8758-66.
35. Dozier C, Bonyadi M, Baricault L, Tonasso L, Darbon JM. Regulation of Chk2 phosphorylation by interaction with protein phosphatase 2A via its B' regulatory subunit. Biol Cell 2004; 96:509-17.
36. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001; 21:4129-39.
37. Gatei M, Sloper K, Sorensen C, Syljuasen R, Falck J, Hobson K, et al. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 2003; 278:14806-11.
38. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273:5858-68.
39. Goodarzi AA, Jonnalagadda JC, Douglas P, Young D, Ye R, Moorhead GB, et al. Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J 2004; 23:4451-61. (Pubitemid 39601970)
40. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 1998; 58:4375-82.
41. Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006; 26:7529-38. (Pubitemid 44547703)
42. Li G, Elder RT, Qin K, Park HU, Liang D, Zhao RY. Phosphatase type 2A-dependent and -independent pathways for ATR phosphorylation of Chk1. J Biol Chem 2007; 282:7287-98. (Pubitemid 47093684)
43. Mi J, Bolesta E, Brautigan DL, Larner JM. PP2A regulates ionizing radiation-induced apoptosis through Ser46 phosphorylation of p53. Mol Cancer Ther 2009; 8:135-40.
44. McConnell JL, Gomez RJ, McCorvey LR, Law BK, Wadzinski BE. Identification of a PP2A-interacting protein that functions as a negative regulator of phosphatase activity in the ATM/ATR signaling pathway. Oncogene 2007; 26:6021-30.
45. Petersen P, Chou DM, You Z, Hunter T, Walter JC, Walter G. Protein phosphatase 2A antagonizes ATM and ATR in a Cdk2- and Cdc7-independent DNA damage checkpoint. Mol Cell Biol 2006; 26:1997-2011.
46. Chowdhury D, Keogh MC, Ishii H, Peterson CL, Buratowski S, Lieberman J. gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell 2005; 20:801-9.
47. Liang X, Reed E, Yu JJ. Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr- 68 after cisplatin treatment of human ovarian cancer cells. Int J Mol Med 2006; 17:703-8.
48. Fujimoto H, Onishi N, Kato N, Takekawa M, Xu XZ, Kosugi A, et al. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ 2006; 13:1170-80.
49. Oliva-Trastoy M, Berthonaud V, Chevalier A, Ducrot C, Marsolier-Kergoat MC, Mann C, et al. The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase. Oncogene 2007; 26:1449-58.
50. Yoda A, Xu XZ, Onishi N, Toyoshima K, Fujimoto H, Kato N, et al. Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1. J Biol Chem 2006; 281:24847-62.
51. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999; 59:4375-82.